Rezension:
A Second Class stamp hermes birkin Celgene\'s new multiple myeloma treatment, Pomalyst, sold $66 million in its first full quarter of sales. The drug was approved by the U.S. Food and Drug Administration in February and is expected to reach the billion-dollar sales mark by 2016.
